Literature DB >> 24041161

Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.

Kogularamanan Suntharalingam1, Timothy C Johnstone, Peter M Bruno, Wei Lin, Michael T Hemann, Stephen J Lippard.   

Abstract

The cellular response evoked by antiproliferating osmium(VI) nitrido compounds of general formula OsN(N^N)Cl3 (N^N = 2,2'-bipyridine 1, 1,10-phenanthroline 2, 3,4,7,8-tetramethyl-1,10-phenanthroline 3, or 4,7-diphenyl-1,10-phenanthroline 4) can be tuned by subtle ligand modifications. Complex 2 induces DNA damage, resulting in activation of the p53 pathway, cell cycle arrest at the G2/M phase, and caspase-dependent apoptotic cell death. In contrast, 4 evokes endoplasmic reticulum (ER) stress leading to the upregulation of proteins of the unfolded protein response pathway, increase in ER size, and p53-independent apoptotic cell death. To the best of our knowledge, 4 is the first osmium compound to induce ER stress in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24041161      PMCID: PMC3791136          DOI: 10.1021/ja4075375

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  49 in total

1.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 2.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

Authors:  Christian G Hartinger; Stefanie Zorbas-Seifried; Michael A Jakupec; Bernd Kynast; Haralabos Zorbas; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2006-02-28       Impact factor: 4.155

3.  Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

Authors:  Anna F A Peacock; Abraha Habtemariam; Rafael Fernández; Victoria Walland; Francesca P A Fabbiani; Simon Parsons; Rhona E Aird; Duncan I Jodrell; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2006-02-08       Impact factor: 15.419

4.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

5.  Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives.

Authors:  Kosuke Dodo; Miho Katoh; Tadashi Shimizu; Masahiro Takahashi; Mikiko Sodeoka
Journal:  Bioorg Med Chem Lett       Date:  2005-06-15       Impact factor: 2.823

Review 6.  Targeting the endoplasmic reticulum-stress response as an anticancer strategy.

Authors:  Sandra J M Healy; Adrienne M Gorman; Parisa Mousavi-Shafaei; Sanjeev Gupta; Afshin Samali
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

7.  The expression of p53, p21, Bax and induction of apoptosis in normal volunteers in response to different doses of ultraviolet radiation.

Authors:  M Murphy; M J E M F Mabruk; P Lenane; A Liew; P McCann; A Buckley; P Billet; M Leader; E Kay; G M Murphy
Journal:  Br J Dermatol       Date:  2002-07       Impact factor: 9.302

8.  DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media.

Authors:  Hana Kostrhunova; Jakub Florian; Olga Novakova; Anna F A Peacock; Peter J Sadler; Viktor Brabec
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.

Authors:  Ying Fu; Abraha Habtemariam; Aida M B H Basri; Darren Braddick; Guy J Clarkson; Peter J Sadler
Journal:  Dalton Trans       Date:  2011-08-22       Impact factor: 4.390

View more
  28 in total

1.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Authors:  Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

Review 2.  Third row transition metals for the treatment of cancer.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2015-03-13       Impact factor: 4.226

3.  Platinum compounds for high-resolution in vivo cancer imaging.

Authors:  Miles A Miller; Bjorn Askevold; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

4.  A Rhenium Isonitrile Complex Induces Unfolded Protein Response-Mediated Apoptosis in Cancer Cells.

Authors:  A Paden King; Sierra C Marker; Robert V Swanda; Joshua J Woods; Shu-Bing Qian; Justin J Wilson
Journal:  Chemistry       Date:  2019-06-26       Impact factor: 5.236

5.  Solid-phase synthesis as a platform for the discovery of new ruthenium complexes for efficient release of photocaged ligands with visible light.

Authors:  Rajgopal Sharma; Jessica D Knoll; Nicholas Ancona; Phillip D Martin; Claudia Turro; Jeremy J Kodanko
Journal:  Inorg Chem       Date:  2015-01-22       Impact factor: 5.165

6.  Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.

Authors:  Mickaël Marloye; Haider Inam; Connor J Moore; Vinciane Debaille; Justin R Pritchard; Michel Gelbcke; Franck Meyer; François Dufrasne; Gilles Berger
Journal:  J Biol Inorg Chem       Date:  2021-06-26       Impact factor: 3.358

7.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

8.  Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin.

Authors:  Imogen A Riddell; Timothy C Johnstone; Ga Young Park; Stephen J Lippard
Journal:  Chemistry       Date:  2016-04-25       Impact factor: 5.236

9.  An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols.

Authors:  Ka-Chung Tong; Chun-Nam Lok; Pui-Ki Wan; Di Hu; Yi Man Eva Fung; Xiao-Yong Chang; Song Huang; Haibo Jiang; Chi-Ming Che
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-02       Impact factor: 11.205

10.  Enzymatic Assemblies Disrupt the Membrane and Target Endoplasmic Reticulum for Selective Cancer Cell Death.

Authors:  Zhaoqianqi Feng; Huaimin Wang; Shiyu Wang; Qiang Zhang; Xixiang Zhang; Avital A Rodal; Bing Xu
Journal:  J Am Chem Soc       Date:  2018-07-24       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.